IBX Phase 2 Clinical Trial Update
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The manufacturing of the investigational product is complete, and it is ready for distribution to trial sites. Contract negotiations with the first clinical trial site in the USA have begun, and initiation activities are in progress with several prospective sites. The imaging protocol has been finalized, incorporating advanced quantitative MRI techniques.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Imagion Biosystems Ltd. on 6ix
Story so far
Earlier from Imagion Biosystems
- Appendix 4C and Quarterly Activities Report - June 2026
- Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
- IBX Secures Firm Commitments for $3.75m for Clinical Trial
- Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
- Imagion Biosystems Receives IND Clearance from US FDA
Later from Imagion Biosystems
- MagSense Nanoparticle Manufacturing Update
- Imagion Resumes MagSense® Nanoparticle Manufacturing Capabilities
- IBX Secures Central Ethics Approval - Key Phase 2 Milestone
- Appendix 4C and Quarterly Activities Report - September 2026
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems